Mercer Global Advisors
NGNE icon

Mercer Global Advisors’s Neurogene NGNE Stock Holding History

Mercer Global Advisors’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45K Buy
+1,432
New +$39.4K ﹤0.01% 4363

Other funds holding NGNE

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Mercer Global Advisors's NGNE Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Neurogene (NGNE) in Q2 2026: 1,432 shares worth $45K. The stake represents ﹤0.01% of the portfolio and ranks #4363 among its holdings.

102 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • Mercer Global Advisors held 1,432 shares of Neurogene worth $45K as of Q2 2026.
  • Neurogene was a new Mercer Global Advisors position in Q2 2026.
  • Neurogene made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #4363 holding.
  • 102 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.